Equity · Healthcare
ROIV
Roivant Sciences Ltd. · NasdaqGS
The line runs $35.07 on 1 July through $40.82 on 11 September, on a scale from $32.5 to $42.5. Days the market did not trade hold the previous close, flat.
The chart above plots the price of ROIV over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 44 sessions over that window: $35.07 on 1 July 2026 through $40.82 on 11 September 2026.
Finazon · prior-day close, indicative (IEX-derived, not the official close) · valuation computed from SEC EDGAR filings · as of Sep 11, 2026
ROIV insider trades
Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.
Showing the 12 most recent of 27 compensation filings in this window. The figures above count all of them.
ROIV reported financials
ROIV reported revenue of $8.3M for the fiscal year ended 31 Mar 2026. Net income over the same period was −$299.8M.
Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
ROIV earnings
no date announced in SEC filings yet
Reported figures & scheduled dates · SEC EDGAR filings
ROIV institutional holders
12 of the 45 institutional funds we track reported a ROIV position for the quarter ended 30 Jun 2026 — a combined $1.3B; the latest of those filings landed 02 Sep 2026.
Showing the 10 largest of 12 reported positions. The figures above count all of them.
Source: SEC EDGAR 13F filings
ROIV fails-to-deliver
On 21 Aug 2026, 2,028 shares of ROIV failed to deliver (about $75K) — the latest of 2 consecutive trading days with recorded fails.
Source: SEC fails-to-deliver (CNS) data